INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR

Core Viewpoint - Pharming Group N.V. is under investigation for potential securities fraud following the FDA's Complete Response Letter regarding its drug Joenja® [1][2] Group 1: Company Overview - Pharming Group N.V. is a biopharmaceutical company focused on developing innovative therapies for rare diseases [2] - The company’s stock, represented by American Depositary Receipts (ADRs), experienced a significant decline of 17.07% following negative FDA news [2] Group 2: FDA Response - On February 1, 2026, the FDA issued a Complete Response Letter for Pharming's supplemental New Drug Application for Joenja® [2] - The FDA raised concerns about potential underexposure in lower weight pediatric patients and requested additional pharmacokinetic data [2] - An issue was also identified with one of the analytical methods used for production batch testing, necessitating further data and clarification [2] Group 3: Legal Investigation - Pomerantz LLP is investigating claims on behalf of Pharming investors regarding possible securities fraud or unlawful business practices by the company and its officers [1] - The firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud [3]